ClinicalTrials.gg
CompletedNCT02608970Updated Jul 31, 2017

Safety and Tolerability Study of BMS-986177 in Healthy Subjects

A Phase 1 interventional study of BMS-986177 and Placebo in Thrombosis, sponsored by Bristol-Myers Squibb. Completed at 1 site in Belgium. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-07-31.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Thrombosis by Bristol-Myers Squibb — none open to participants now, none under way, none of them phase 3. Thrombosis · Bristol-Myers Squibb.

Enrollment
7th of 19
104 · median 42
Started
2015
with 2 others
Phase 1
13 of 19
none open now
Registered
7th of 19
by date

Among the 19 studies in Thrombosis by Bristol-Myers Squibb, this one is the 7th largest by enrollment, is one of 3 that started in 2015, is one of 13 in phase 1, and was the 7th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

None of the 19 studies in Thrombosis by Bristol-Myers Squibb is open now. The open studies under Thrombosis, anywhere →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Thrombosis by Bristol-Myers Squibb as a file.
02

Study summary

The purpose of this study is to determine the safety, tolerability, and pharmacokinetics of BMS-986177 in healthy subjects

03

Conditions studied

  • Thrombosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion criteria

Inclusion Criteria:

  • Healthy subjects as determined by no deviation from normal in medical history, physical examination, ECGs and clinical laboratory determinations
  • (BMI) of 18 to 30 kg/m2 inclusive. BMI = weight (kg)/ [height (m)]2
  • Females who are not of (i.e., who are or surgically sterile) and men ages 18 to 55, inclusive

Exclusion criteria

Exclusion Criteria:

  • Evidence of organ dysfunction or any deviation from normal in physical examination, vital signs, or clinical laboratory determinations beyond what is consistent with the target population
  • Any condition that could affect drug absorption
  • Other protocol-defined exclusion criteria could apply
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    BMS-986177

    BMS-986177 specified dose on specified days

    Drug: BMS-986177

  • Other
    Placebo

    Placebo specified dose on specified days

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Safety of single dose of BMS-986177 measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Adverse event (AE), Serious adverse event (SAE)

    Time frame: Approximately 3 days

  2. Safety of multiple dose of BMS-986177 measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Time frame: Approximately 16 days

  3. Tolerability of single dose of BMS-986177 measured by number of subjects who experience SAEs, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Time frame: Approximately 3 days

  4. Tolerability of multiple dose of BMS-986177 measured by number of subjects who experience SAE, deaths, AEs leading to discontinuation, and potential clinically significant changes in ECG parameters, vital signs, laboratory tests and physical examinations

    Time frame: Approximately 16 days

07

Study locations

1 site
  • SGS Belgium NV
    Antwerpen, 2060, Belgium
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2015 to primary completion in Jul 2017, 18 months.

Of 30 phase 1 interventional studies under Thrombosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 30. This study's 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2015
First posted
Nov 20, 2015
StartActual
Dec 31, 2015
Primary completionActual
Jul 23, 2017
CompletionActual
Jul 23, 2017
Last update
Jul 31, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02608970
Responsible party
Sponsor
First posted
Nov 20, 2015
Start date
Dec 31, 2015
Primary completion
Jul 23, 2017
Completion
Jul 23, 2017
Last update
Jul 31, 2017

Study contacts

Bristol Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milvexian

Start the discussion